Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Common Equity (2020 - 2025)

SAB Biotherapeutics' Common Equity history spans 6 years, with the latest figure at $151.5 million for Q4 2025.

  • For Q4 2025, Common Equity rose 483.35% year-over-year to $151.5 million; the TTM value through Dec 2025 reached $151.5 million, up 483.35%, while the annual FY2025 figure was $151.5 million, 483.35% up from the prior year.
  • Common Equity reached $151.5 million in Q4 2025 per SABSW's latest filing, down from $165.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $165.1 million in Q3 2025 to a low of $12.0 million in Q2 2025.
  • Average Common Equity over 5 years is $46.1 million, with a median of $37.0 million recorded in 2022.
  • The largest YoY upside for Common Equity was 483.35% in 2025 against a maximum downside of 73.95% in 2025.
  • A 5-year view of Common Equity shows it stood at $38.5 million in 2021, then dropped by 19.43% to $31.1 million in 2022, then soared by 84.49% to $57.3 million in 2023, then plummeted by 54.68% to $26.0 million in 2024, then skyrocketed by 483.35% to $151.5 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Common Equity are $151.5 million (Q4 2025), $165.1 million (Q3 2025), and $12.0 million (Q2 2025).